Nanotrope Awarded NASA Phase 2 Grant

Nanotrope Inc. has announced that it has been awarded a $600,000 Phase 2 grant from the National Aeronautics and Space Administration (NASA) for research in nanoscale droplet technology to enhance drug delivery.

Based on technical merit and innovation, only a select number of Small Business Innovation Research (SBIR) Phase 2 grants were awarded.

Nanotrope plans to use the proceeds to advance technology for new drug formulations and delivery protocols.

The company's winning proposal considered both NASA deep space initiatives as well as non-NASA commercial applications.
   
"Nanotrope is especially excited to have won the NASA SBIR grant which is awarded to a select group of businesses," said Dr. Donald Ackley president and CEO for Nanotrope Inc.

"With this funding from NASA, our research will allow us to rapidly move forward on applying nanodroplet technology toward targeted drug delivery."
   
Nanotrope's nanoscale droplet technology has positive implications for NASA, the pharmaceutical industry, and patients.

In a complex process combining microfluidics and nanotechnology, Nanotrope's nanodroplet generator technology can produce drug "containers" that carry specific delivery instructions that enable the targeting of diseased cells and organs.

The innovation of these high-precision drug formulations will allow drug companies to develop effective and safer drugs.

Patients will benefit from targeted drugs as the new drugs would affect only the unhealthy cells or organs, versus all-over drug treatments - such as chemotherapy - which can damage otherwise healthy areas.